Original from: genomeweb

Myriad Genetics, Clairity, and MagView said on 25 Nov that they have integrated their products to improve personalized breast cancer risk assessment. 

Clairity, based in Boston, offers a US Food and Drug Administration-authorized AI platform called Clairity Breast that estimates a woman's five-year risk of developing breast cancer from a routine screening mammogram. 

Salt Lake City-based Myriad's MyRisk Hereditary Cancer Test with RiskScore combines genetic testing data, including a polygenic risk score, with clinical factors to predict hereditary cancer risk. 

Under the collaboration, users can now view results from both companies' assessments through MagView's Luminary Risk platform, a software used by more than 2,500 breast imaging centers in the US that can be embedded into electronic health records.

"Integrating Clairity and MyRisk into one platform gives providers a powerful, unified tool to support proactive breast health management, while improving workflow efficiency," said Bryan Chapin, president and CEO of Fulton, Maryland-based MagView, in a statement.

Source: Myriad Genetics, Clairity Integrate Breast Cancer Risk Assessments With MagView Software